Long-term effects of short hairpin RNA-targeted human telomerase reverse transcriptase on suppression of SGC-7901 cell proliferation by inhibition of telomerase activity

Oncology Reports

Volumn 19, Issue 2, 2008, Pages 575-581

  Qian, Xiaobin ^a,b   Cheng, Jing ^b   Chen, Aiping ^b   Wang, Ying ^b   Tao, Yan ^b   Cao, Jianping ^c   Feng, Zhenqing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b JIANGSU UNIVERSITY   (China)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Cancer gene therapy; Human telomerase reverse transcriptase; RNA interference

Indexed keywords

ANTIBIOTIC AGENT; SHORT HAIRPIN RNA; TELOMERASE REVERSE TRANSCRIPTASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; EXPRESSION VECTOR; GENE EXPRESSION; HUMAN; HUMAN CELL; LONG TERM CARE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STOMACH CARCINOMA;

EID: 38749107524     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.2.575     Document Type: Article

References (37)

1. Wilda M, Fuchs U and Borkhardt A: Killing of leukemic cells with a BCR/ ABL fusion gene by RNA interference (RNAi). Oncogene 21: 5716-5724, 2002.
2. Jacque JM, Triques K and Stevenson M: Modulation of HIV-1 replication by RNA interference. Nature 418: 435-438, 2002.
3. Shlomai A and Shaul Y: Inhibition of hepatitis B virus expression replication by RNA interference. Hepatology 37: 764-770, 2003.
4. Kapadia SB, Brideau-Andersen A and Chisari FV: Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci USA 100: 2014-2018, 2003.
5. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994.
6. ABI Prism 7700 Sequence Detection System User Bulletin #2 (2001). Relative quantification of gene expression, http://docs.appliedbisoystems.com/pebiodocs/04303859.pdf.
7. Tong QS, Zeng FQ, Zheng LD, Zhao J and Lu G: Apoptosis inducing effects of arsenic trioxide on human bladder cancer cell line BIU-87. Chin Med J 114: 402-406, 2001.
8. Blackburn EH: Structure and function of telomeres. Nature 350: 569-573, 1991.
9. de Lange T: Protection of mammalian telomeres. Oncogene 21: 532-540, 2002.
10. Harrington L and Robinson MO: Telomere dysfunction: Multiple paths to the same end. Oncogene 21: 592-597, 2002.
11. Morin GB: The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 59: 521-529, 1989.
12. Zhang X, Mar V, Zhou W, Harrington L and Robinson MO: Telomere shortening and apoptosis in telomerase-inhibited human tumor cell. Genes Dev 13: 2388-2399, 1999.
13. de Souza Nascimento P, Alves G and Fiedler W: Telomerase inhibition by an siRNA directed against hTERT leads to telomere attrition in HT29 cells. Oncol Rep 16: 423-428, 2006.
14. Herbert BS, Pitts AE, Baker SI, Hamilton SE, Wright WE, Shay JW, et al: Inhibition of human telomerase in immortal cells lead to progressive telomere shortening and cell death. Proc Natl Acad Sci USA 96: 14276-14281, 1999.
15. Paoloni M, Gunderman JR, Estelle LN, Padilla M and Argyle DJ: Targeting the RNA component of telomerase through RNA interference and the development of vector delivery systems. Vet Comp Oncol 3: 33-34, 2005.
16. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, et al: The RNA component of human telomerase. Science 269: 1236-1241, 1995.
17. Hahn WC: Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol 21: 2034-2043, 2003.
18. Masutomi K, Yu EK, Khurts S, Ben-Porath I, Currier JL, Metz GB, et al: Telomerase maintains telomere structure in normal human cells. Cell 114: 241-253, 2003.
19. Li S, Rosenberg JE, Donjacour AA, Botchkina IL, Hom YK, Cunha GR, et al: Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA. Cancer Res 64: 4833-4840, 2004.
20. Kraemer K, Fuessel S, Schmidt U, Kotzsch M, Schwenzer B, Wirth MP, et al: Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res 10: 3794-3800, 2003.
21. Akiyama M, Yamada O, Kanda N, Akita S, Kawano T, Onho T, et al: Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors. Cancer Lett 178: 187-197, 2002.
22. Elbashir SM, Lendeckel W and Tuschl T: RNA interference is mediated by -21 and -22 nucleotide RNAs. Genes Dev 15: 188-200, 2001.
23. Wall NR, Shi Y and Small RNA: Can RNA interference be exploited for therapy? Lancet 362: 1401-1403, 2003.
24. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, et al: RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival and tumorigenicity in vivo. J Biol Chem 280: 36529-36540, 2005.
25. Zamor PD: RNA interference: Listening to the sound of silence. Nat Struct Bio 8: 746-750, 2001.
26. Lakka SS, Gondi CS, Dinh DH, Olivero WC, Gujrati M, Rao VH, et al: Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth and angiogenesis in gliomas. J Biol Chem 280: 21882-21892, 2005.
27. Huang SL, Wu Y, Yu H, Zhang P, Zhang XQ, Ying L, et al: Inhibition of Bcl-2 expression by a novel tumor-specific RNA interference system increases chemosensitivity to 5-fluorouracil in Hela cells. Acta Pharmacol Sin 27: 242-248, 2006.
28. Downward J: Use of RNA interference libraries to investigate oncogenic signaling in mammalian cells. Oncogene 23: 8376-8383, 2004.
29. Zhang MS, Zhou YF, Xie CH, Zhou F, Chen Y, Han G, et al: STAT6 specific shRNA inhibits proliferation and induces apoptosis in colon cancer HT-29 cells. Cancer Lett 243: 38-46, 2006.
30. Sui G, Soohoo C, el Affar B, Gay F, Shi Y, Forrester WC, et al: A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 99: 5515-5520, 2002.
31. Hu XQ, Su FX, Qin L, Jia W, Gong C, Yu F, et al: Stable RNA interference of ErbB-2 gene synergistic with epirubicin suppresses breast cancer growth in vitro and in vivo. Biochem Biophys Res Commun 346: 778-785, 2006.
32. Brummelkamp TR, Bernards R and Agami R: System for stable expression of short interfering RNAs in mammalian cells. Science 296: 550-553, 2002.
33. Xia Y, Lin RX, Zheng SJ, Yang Y, Bo XC, Zhu DY and Wang SQ: Effective siRNA targets screening for human telomerase reverse transcriptase. World J Gastroenterol 11: 2497-2501, 2005.
34. Zhang PH, Zou L and Tu ZHG: RNAi-hTERT inhibition hepatocellular carcinoma cell proliferation via decreasing telomerase activity. J Surg Res 131: 143-149, 2006.
35. Massard C, Zermati Y, Pauleau AL, Larochette N, Métivier D, Sabatier L, Kroemer G, et al: hTERT: A novel endogenous inhibitor of the mitochondrial cell death pathway. Oncogene 25: 4505-4514, 2006.
36. Gandellini P, Folini M, Bandiera R, De Cesare M, Binda M, Veronese S and Daidone MG: Down-regulation of human telomerase reverse transcriptase through specific activation of RNAi pathway quickly results in cancer cell growth impairment. Biochem Pharmacol 73: 1703-1714, 2007.
37. Kurvinen K, Syrjänen S and Johansson B: Long-term suppression of telomerase expression in HeLa cell clones, transfected with an expression vector carrying siRNA targeting hTERT mRNA. Int J Oncol 29: 279-288, 2006.